Abstract
BackgroundPrevious studies have reported that transplantation of mesenchymal stem cells (MSCs) from many human tissues could ameliorate ovarian dysfunction. However, no study has revealed the therapeutic efficiency of MSCs derived from the chorionic plate (CP-MSCs) for premature ovarian failure (POF).MethodsWe investigated the restorative effects of CP-MSCs on cyclophosphamide (CTX)-induced POF. The POF mouse models were established via intraperitoneal injection of 50 mg/kg CTX into female mice for 15 consecutive days. After that, CP-MSCs were intravenously transplanted into the mice once a week for 4 weeks. The serum estradiol (E2) and follicle-stimulating hormone (FSH) levels in the mouse models were detected using enzyme-linked immunosorbent assay (ELISA) before and after treatment. Ovarian function was evaluated through counting the follicles, estrous cycles, and oocytes.ResultsCP-MSC transplantation restored the serum hormone level and ovarian function of the mice in the mouse model of POF induced by CTX. The levels of serum E2 and FSH in the POF model group was 232.33 ± 17.16 pg/mL and 4.48 ± 0.29 mIU/mL, respectively, after 6 weeks of treatment, which were similar to the values in the wild-type (WT) group. The superovulation demonstrated that ovarian function was significantly improved compared with nontreated POF model mice. The CP-MSC transplantation could restore CTX-induced ovarian dysfunction.ConclusionsOur results offer a potential application for human CP-MSCs in POF treatment.
Highlights
Previous studies have reported that transplantation of mesenchymal stem cells (MSCs) from many human tissues could ameliorate ovarian dysfunction
Preparation and identification of Chorionic plate-derived mesenchymal stem cell (CP-MSC) In the present study, we designed and synthesized CPMSCs from human placenta according to the requirements of current good manufacturing practice (cGMP)-compliant procedures
Since CP-MSCs at the fifth passage were used for stem cell transplantation, karyotyping was carried out to assess the safety of CP-MSCs
Summary
Previous studies have reported that transplantation of mesenchymal stem cells (MSCs) from many human tissues could ameliorate ovarian dysfunction. Li et al Stem Cell Research & Therapy (2018) 9:81 autosomal gene mutations [2, 3] Iatrogenic insults, such as after chemotherapy and radiation treatment for cancer, occasionally can damage ovarian function leading to premature menopause, ovarian dysfunction, and risk of infertility [1]. Human bone marrowderived mesenchymal stem cells (BM-MSCs) were the first stem cells reported to enhance ovarian function and structure in a rat model with chemotherapy-induced ovarian damage [5,6,7]. The therapeutic potential of MSCs from placental tissues in POF has not been explored
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
